WO2022202072A1 - Instrument médical - Google Patents

Instrument médical Download PDF

Info

Publication number
WO2022202072A1
WO2022202072A1 PCT/JP2022/007488 JP2022007488W WO2022202072A1 WO 2022202072 A1 WO2022202072 A1 WO 2022202072A1 JP 2022007488 W JP2022007488 W JP 2022007488W WO 2022202072 A1 WO2022202072 A1 WO 2022202072A1
Authority
WO
WIPO (PCT)
Prior art keywords
needle
inner needle
perforation
lumen
retina
Prior art date
Application number
PCT/JP2022/007488
Other languages
English (en)
Japanese (ja)
Inventor
英里子 伊藤
佳久 島村
領 田中
陽一郎 岩瀬
祐亮 百貫
Original Assignee
テルモ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テルモ株式会社 filed Critical テルモ株式会社
Publication of WO2022202072A1 publication Critical patent/WO2022202072A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery

Definitions

  • the present invention relates to a medical device used for administering drugs into the subretinal space.
  • Vitreoretinal surgery involves administering drugs into the subretinal space (the space between the retina and retinal pigment epithelial cells) or using prescribed therapeutic instruments in the subretinal space, depending on the symptoms and progression of the disease. Take action.
  • Patent Document 1 proposes a catheter device that enables access to the subretinal space from outside the patient's eye.
  • access to the subretinal space is made possible by forming a perforation (opening) in a part of the retina with the catheter device. It discloses procedures such as occluding the perforation after completing the administration of the drug at the.
  • Patent Document 1 mentions a method of denaturing the tissue around the perforation by laser irradiation or cooling as a method for closing the perforation formed in the retina.
  • these methods are adopted, the following points become a problem.
  • the present invention has been made to solve the above-described problems, and can administer a drug into the subretinal space, and can easily and more reliably close a perforation formed in the retina.
  • the purpose is to provide medical equipment.
  • a medical device for achieving the above object has an inner needle for forming a perforation in a patient's retina, and an outer needle having a lumen capable of accommodating the inner needle, the inner needle being a retina of the patient.
  • the outer needle comprises a lumen capable of delivering a drug to be administered intraluminally and is configured to be movable along the lumen of the outer needle, the outer needle providing an occluding device for occluding the perforation. It is configured to be able to eject the agent.
  • an operator for example, a medical worker such as a doctor
  • the inner needle can be protruded from the outer needle to form a perforation in the retina.
  • the operator can administer the drug into the subretinal space by delivering the drug through the lumen of the inner needle while placing the tip of the inner needle in the subretinal space.
  • the operator can discharge the occlusive agent through the outer needle while the inner needle is retracted into the lumen of the outer needle.
  • the operator Before and after forming the perforation, the operator can hold the tip of the outer needle in a state of being positioned near a predetermined position on the retina. Therefore, the operator can apply the occluding agent to an appropriate position of the retina, and can easily and more reliably close the perforation with the occluding agent.
  • FIG. 1 is a diagram showing a simplified overall configuration of a medical instrument according to a first embodiment
  • FIG. FIG. 2 is a cross-sectional view along the arrow 2A-2A line shown in FIG. 1; 2 is a cross-sectional view showing a modification of the medical instrument shown in FIG. 1
  • FIG. 4 is a flow chart showing a surgical procedure using the medical instrument according to the first embodiment
  • FIG. 4 is a diagram schematically showing a procedure using the medical instrument according to the first embodiment
  • FIG. 4 is a diagram schematically showing a procedure using the medical instrument according to the first embodiment
  • FIG. 4 is a diagram schematically showing a state in which a perforation formed in the retina is occluded with an occlusive agent.
  • FIG. 5 is a diagram showing a simplified overall configuration of a medical instrument according to a second embodiment; 11A is a cross-sectional view taken along the line of arrows 11A-11A shown in FIG. 10; FIG. FIG. 11 is a cross-sectional view showing a modification of the medical device shown in FIG. 10;
  • FIG. 10 is a diagram schematically showing a procedure using the medical instrument according to the second embodiment;
  • FIG. 10 is a diagram schematically showing a procedure using the medical instrument according to the second embodiment;
  • FIG. 10 is a diagram schematically showing a procedure using the medical instrument according to the second embodiment;
  • FIG. 10 is a diagram schematically showing a procedure using the medical instrument according to the second embodiment; FIG.
  • FIG. 10 is a diagram schematically showing a procedure using the medical instrument according to the second embodiment
  • FIG. 11 is a diagram showing a simplified overall configuration of a medical instrument according to a third embodiment
  • FIG. 11 is a diagram showing a simplified overall configuration of a medical instrument according to a fourth embodiment
  • 19A is a cross-sectional view taken along line 19A-19A shown in FIG. 18
  • FIG. 19 is a cross-sectional view showing a modification of the medical device shown in FIG. 18;
  • the medical device 100 can be used for a procedure of administering a drug d1 into the subretinal space A of a patient, as shown in FIGS.
  • Administration of drug d1 can be performed, for example, as part of vitreoretinal surgery, which is a method of treating vitreoretinal disease.
  • vitreoretinal surgery which is a method of treating vitreoretinal disease.
  • the purpose of the procedure using the medical device 100 there are no particular restrictions on the purpose of the procedure using the medical device 100, the specific disease to be treated, or the like.
  • the medical device 100 includes an inner needle 120 for forming a perforation P in a patient's retina R, and an outer needle 130 having a lumen 131 capable of accommodating the inner needle 120. , has
  • the inner needle 120 and the outer needle 130 constitute an insertion section 110 that is inserted into the patient's eye.
  • the operator can accommodate the inner needle 120 in the lumen 131 of the outer needle 130 when delivering the insertion portion 110 to the retina R as shown in FIG. 5 .
  • the operator can prevent the inner needle 120 from being erroneously punctured in an unnecessary portion of the patient's eye, and the inner needle 120 from breaking or kinking during delivery to the retina R.
  • the longitudinal direction (extending direction) of the inner needle 120 and the outer needle 130 is indicated by arrows X1-X2.
  • the direction indicated by the arrow X1 is the distal end side of the medical device 100, and indicates the direction of insertion into the patient's eye.
  • the direction indicated by the arrow X2 points toward the proximal end of the medical device 100 .
  • the inner needle 120 comprises a lumen 121 capable of delivering a drug d1 to be administered into the subretinal space A of the patient. Also, the inner needle 120 is configured to be movable along the lumen 131 of the outer needle 130 .
  • a proximal hub 140 is arranged on the proximal end side of the outer needle 130 .
  • the hand hub 140 includes a slide operation portion 143 for operating the forward/backward movement of the inner needle 120 with respect to the outer needle 130 .
  • a portion of the proximal end portion of the inner needle 120 is connected to the slide operating portion 143 inside the proximal hub 140 .
  • the operator can advance the inner needle 120 as indicated by the arrow f2 in conjunction with the advancement.
  • the inner needle 120 By advancing the inner needle 120 by a predetermined distance, the distal end portion of the inner needle 120 can be projected further to the distal end side than the distal end portion of the outer needle 130 .
  • the operator can retract the inner needle 120 as indicated by the arrow b2 in conjunction with the retraction.
  • the inner needle 120 By retracting the inner needle 120 by a predetermined distance, the distal end of the inner needle 120 can be housed in the lumen 131 of the outer needle 130 .
  • the operator can switch between protruding and retracting the inner needle 120 by a simple operation of sliding the slide operation section 143 provided on the hand hub 140 as described above.
  • the outer needle 130 is configured to eject a blocking agent d2 for blocking the perforation P formed in the retina R.
  • a tube 250 can be inserted into the lumen 131 of the outer needle 130 for supplying the occlusive agent d2.
  • the medical device 100 can discharge the occluding agent d2 to the distal end side of the outer needle 130 through the tube 250.
  • the medical device 100 may not have the tube 250 inserted into the lumen 131 of the outer needle 130 as in the modification shown in FIG. When configured in this manner, the medical device 100 can directly discharge the occluding agent d2 through the lumen 131 of the outer needle 130 .
  • a port 141 is arranged to which a syringe 210 for supplying the drug d1 can be connected.
  • Lumen 121 of inner needle 120 communicates with the interior of port 141 via the interior of proximal hub 140 .
  • lumen 121 of inner needle 120 is isolated within lumen 131 of outer needle 130 . Therefore, the medical device 100 can prevent the drug d1 flowing inside the lumen 121 of the inner needle 120 and the blocking agent d2 flowing outside the lumen 121 of the inner needle 120 from being mixed.
  • the inner needle 120 and the outer needle 130 have a shape extending substantially linearly in the longitudinal direction.
  • the inner needle 120 and the outer needle 130 can also be composed of curved needles (see FIG. 10).
  • the outer needle 130 can be composed of a metal needle.
  • the inner needle 120 can be configured with a resin needle that is more flexible than the outer needle 130 .
  • the outer needle 130 By configuring the outer needle 130 with a metal needle, it is possible to prevent the needles 120, 130 from breaking or kinking when delivering the needles 120, 130 to the retina R (see FIG. 5). Further, by configuring the inner needle 120 with a flexible resin needle, it is possible to prevent the inner needle 120 from breaking through the eye when puncturing the retina R (see FIG. 7).
  • the inner needle 120 can be made of, for example, polyurethane, Teflon (registered trademark), polyester, polyimide, or the like.
  • the outer needle 130 can be made of, for example, stainless steel, nitinol, tungsten, or the like.
  • the inner needle 120 and the outer needle 130 can be composed of blunt needles, for example. However, the inner needle 120 and/or the outer needle 130 may be composed of sharp needles.
  • outer diameter, needle length, lumen diameter, etc. of the inner needle 120 and the outer needle 130 there are no particular restrictions on the outer diameter, needle length, lumen diameter, etc. of the inner needle 120 and the outer needle 130, and any configuration can be adopted as appropriate.
  • the material of the drug d1 is not particularly limited, for example, low molecules, peptides, antibodies, nucleic acids, cell drugs, viral vector drugs, etc. used for the treatment of retinas such as age-related macular degeneration and hereditary retinal diseases are specifically mentioned.
  • the material of the blocking agent d2 is not particularly limited, for example, a two-liquid mixed biodegradable adhesive can be used.
  • a two-liquid mixed adhesive is used as the occluding agent d2
  • fibrinogen can be used as the first liquid (one component)
  • thrombin can be used as the second liquid (the other component).
  • the medical device 100 is configured such that a tube 250 connected to each syringe 220, 230 for supplying the occluding agent d2 can be connected.
  • the syringe 220 holds the first liquid forming the adhesive
  • the syringe 230 holds the second liquid forming the adhesive.
  • Each syringe 220, 230 is connected with an auxiliary member 260 for synchronizing the movement of the plunger of each syringe 220, 230.
  • the operator can adjust the amount of movement of the plungers of the syringes 220 and 230 to be substantially the same. Thereby, the amounts of the first liquid and the second liquid can be adjusted to be equal.
  • a tube 231 is connected to the tip of the syringe 220 holding the first liquid.
  • a tube 232 is connected to the tip of the syringe 230 holding the second liquid.
  • a confluence port 240 is arranged at the tip of each tube 231 , 232 . The first and second liquids sent from the syringes 220 and 230 are mixed at the confluence port 240 to form an adhesive, and then sent to the outer needle 130 (see FIG. 2) through the tube 250. be done.
  • Fig. 4 shows an outline of the procedure in a flow chart.
  • each procedure other than the administration of the drug d1 using the medical device 100 and the closure of the perforation P with the blocking agent d2 (each procedure employed in general vitreoretinal surgery, such as anesthesia and port injection) will be described. arrangement, etc.) will be omitted.
  • the contents known in the vitreoretinal surgery can be arbitrarily incorporated into the procedure of the present embodiment.
  • the procedure according to the present embodiment is summarized as inserting the insertion portion 110 (the inner needle 120 and the outer needle 130) into the eye (S11), and puncturing the retina R with the inner needle 120. (S12), administering the drug d1 into the subretinal space A through the inner needle 120 (S13), removing the inner needle 120 from the subretinal space A (S14), and the outer needle 130 and closing the perforation P formed in the retina R by ejecting the blocking agent d2 through the retina (S15).
  • S12 administering the drug d1 into the subretinal space A through the inner needle 120
  • S14 removing the inner needle 120 from the subretinal space A
  • S15 the outer needle 130 and closing the perforation P formed in the retina R by ejecting the blocking agent d2 through the retina
  • the operator inserts the insertion portion 110 into the patient's eye as shown in FIG.
  • the operator delivers the tip of the insertion section 110 to a predetermined position on the retina R while the inner needle 120 is housed in the lumen 131 of the outer needle 130 .
  • the operator projects the inner needle 120 from the tip of the outer needle 130 and punctures the retina R with the inner needle 120 .
  • a perforation P is formed in the retina R by puncturing the retina R with the inner needle 120 .
  • the operator administers the drug d1 into the subretinal space A partitioned between the retina R and the retinal pigment epithelial cells E through the lumen 121 of the inner needle 120, as shown in FIG.
  • the operator removes the inner needle 120 from the subretinal space A after administering the drug d1.
  • the operator retracts the inner needle 120 into the lumen 131 of the outer needle 130 .
  • the operator ejects the occlusive agent d2 through the outer needle 130, as shown in FIGS.
  • An occlusive agent d2 is applied to the perforation P formed in the retina R and its peripheral portion.
  • the occlusive agent d2 can be discharged through the lumen 251 of the tube 250 .
  • the occluding agent d2 can be discharged through the lumen 131 of the outer needle 130 .
  • the operator uses the outer needle 130 while puncturing the inner needle 120, administering the drug d1 via the inner needle 120, and ejecting the occlusive drug d2 via the outer needle 130.
  • the operator can hold the position of the tip (needle tip) near the perforation P. Therefore, after the perforation P is formed by the inner needle 120, the operator can appropriately apply the occluding agent d2 to the perforation P and its surroundings without losing sight of the position of the perforation P.
  • the operator can block the perforation P with the perforation P formed in the retina R and the blocking agent d2 ejected to the periphery thereof. After closing the perforation P, the operator removes the insertion portion 110 from the patient's eye.
  • the operator inserts the outer needle 130 and the inner needle 120 into the retina R while the inner needle 120 is accommodated in the lumen 131 of the outer needle 130. Deliver to the desired location.
  • the operator can form a perforation P in the retina R by protruding the inner needle 120 from the outer needle 130 while the tip of the outer needle 130 is arranged near a predetermined position on the retina R.
  • the operator administers the drug d1 into the subretinal space A by delivering the drug d1 through the lumen 121 of the inner needle 120 while placing the tip of the inner needle 120 in the subretinal space A. be able to.
  • the operator withdraws the inner needle 120 into the lumen 131 of the outer needle 130 after administering the drug d1.
  • the operator can discharge the occlusive agent d2 through the outer needle 130 while the inner needle 120 is retracted into the lumen 131 of the outer needle 130 .
  • the operator Before and after forming the perforation P, the operator can hold the position of the distal end portion of the outer needle 130 in the vicinity of the perforation P. Therefore, the operator can appropriately apply the occluding agent d2 to the perforation P and its surrounding area. Thereby, the operator can easily and more reliably close the perforation P with the blocking agent d2.
  • the operator can inject a swelling agent into the subretinal space A to form a wheal before administering the drug d1.
  • a swelling agent By injecting the swelling agent, the operator can confirm whether or not there is a sufficient space in the subretinal space A for injecting the agent d1. Also, the operator can use the wheal as a mark of the position to administer the drug d1.
  • the material of the swelling agent is not particularly limited, and known materials can be used as appropriate.
  • the operator can use the medical device 100 to inject the swelling agent.
  • the operator can use the inner needle 120 of the medical device 100 to form the perforation P and inject the swelling agent into the subretinal space A.
  • the operator can close the perforation P with the blocking agent d2 by the same procedure as described above. These specific procedures are the same as those for administration of drug d1 described above.
  • the operator After forming the wheal, the operator temporarily removes the medical device 100 from the patient's eye.
  • the operator then delivers each needle 120, 130 to the location where the wheal is formed through a predetermined port prepared for administering drug d1, Formation of the perforation P, administration of the drug d1 to the position where the wheal is formed, and closure of the perforation P with the blocking agent d2 can be performed.
  • a medical device 100D see FIG. 18
  • administration of the drug d1 and injection of the swelling agent can be achieved with one medical device.
  • the operator Before forming the perforation P in the retina R, the operator can previously apply the occluding agent d2 to the position where the perforation P is to be formed. By forming the perforation P at the position where the blocking agent d2 is applied, the operator can block the perforation P with the blocking agent d2 as the inner needle 120 is removed from the perforation P.
  • physical properties such as viscosity of the blocking agent d2 are appropriately adjusted so that the perforation P can be automatically closed as the inner needle 120 is removed from the perforation P. be.
  • FIG. 10 to 16 a medical device 100A according to a second embodiment will be described with reference to FIGS. 10 to 16.
  • FIG. the contents already described in the first embodiment (device configuration, procedure, etc.) will be omitted as appropriate.
  • the contents that are not particularly mentioned can be the same as those of the first embodiment described above.
  • the medical device 100A has an inner needle 120A and an outer needle 130A that are curved needles.
  • the specific curvatures and shapes of the inner needle 120A and the outer needle 130A are no particular restrictions.
  • a needle hub 125 is arranged at the proximal end of the inner needle 120A.
  • a syringe 210 can be connected to the needle hub 125 for delivering drug d1.
  • a needle hub 133 is arranged at the proximal end of the outer needle 130A.
  • a tube 250 is connected to the needle hub 133 for supplying the occlusive agent d2.
  • the inner needle 120A is inserted into the lumen 131 of the outer needle 130 via the needle hub 133 of the outer needle 130A (see FIG. 11).
  • the operator can manipulate the movement of the inner needle 120A by gripping the inner needle 120A on the base end side of the needle hub 133 with fingers or the like.
  • the medical device 100A does not need to insert the tube 250 into the lumen 131 of the outer needle 130A like the modification shown in FIG. When configured in this manner, the medical device 100A can discharge the blocking agent d2 through the lumen 131 of the outer needle 130A.
  • the operator delivers the inner needle 120A and the outer needle 130A to a predetermined position in the retina R, and then protrudes the inner needle 120A from the outer needle 130A to form a perforation P in the retina R. .
  • the inner needle 120A is a curved needle
  • the operator moves the inner needle 120A along the subretinal space A (see FIG. 7) partitioned between the retina R and the retinal pigment epithelial cells E. be able to. Therefore, the operator can move the tip of the inner needle 120A to a position away from the perforation P while preventing the inner needle 120A from puncturing the retinal pigment epithelial cells E. Thereby, the operator can administer the drug d1 at a position distant from the perforation P.
  • the puncture direction of the inner needle 120A is guided by the outer needle 130A configured by a curved needle.
  • the operator can prevent the inner needle 120A from puncturing the retina R in a straight line, and can prevent perforations in the retinal pigment epithelial cells E from being formed.
  • the operator After administering the drug d1 into the subretinal space A, the operator ejects the blocking agent d2 through the outer needle 130A, as shown in FIG. The operator can block the perforation P formed at a position distant from the administration position of the drug d1 with the blocking agent d2.
  • the operator can move the inner needle 120A along the subretinal space A by a predetermined distance from the position where the perforation P is formed, as shown in FIG.
  • a perforation P is formed at a position distant from the macula in order to prevent damage to the macula.
  • the operator can form the perforation P at a position separated by a predetermined distance from the administration position of the drug d1. Therefore, it is possible to more reliably prevent damage such as macula from occurring.
  • the operator can block the perforation P by discharging the blocking agent d2 from the outer needle 130A after administering the drug d1.
  • the outer needle 130A need not be a curved needle when performing the procedure described with reference to FIGS. Therefore, only the inner needle 120A may be configured with a curved needle, and the outer needle 130A may be configured with a linear needle.
  • a medical device 100C according to a third embodiment will be described with reference to FIG.
  • the contents already explained in each of the above embodiments (device configuration, procedure, etc.) will be omitted as appropriate.
  • the contents that are not particularly mentioned can be the same as those in each of the above-described embodiments.
  • the medical device 100C has an extension tube 150 connected to the proximal end of the inner needle 120.
  • a needle hub 153 to which a syringe 210 for supplying the drug d1 can be connected is arranged at the proximal end of the extension tube 150 .
  • the extension tube 150 connected to the proximal end of the inner needle 120 facilitates handling of the inner needle 120 outside the patient's eye. Therefore, the procedure using the medical device 100C can be performed more smoothly.
  • FIG. 18 a medical device 100D according to a fourth embodiment will be described with reference to FIGS. 18 to 20.
  • FIG. In the explanation of the fourth embodiment, the contents already explained in each of the above embodiments (device configuration, procedure, etc.) will be omitted as appropriate. In addition, the contents that are not particularly mentioned can be the same as those in each of the above-described embodiments.
  • the medical device 100D inserts a tube 160 connected to a syringe 270 for injecting a swelling agent into the lumen 121 of the inner needle 120.
  • FIG. A hub 163 for connecting a syringe 270 is arranged at the proximal end of the tube 160 .
  • the operator injects the swelling agent into the subretinal space A through the lumen 161 of the tube 160. can do.
  • the operator can inject the drug d1 into the vicinity of the wheal following the work of forming the wheal without replacing the medical device 100D with another medical device. Therefore, by using the medical device 100D, the procedure can proceed more smoothly.
  • the medical device 100D does not need to insert the tube 250 into the lumen 131 of the outer needle 130 like the modified example shown in FIG. When configured in this manner, the medical device 100D can discharge the occluding agent d2 through the lumen 131 of the outer needle 130 .
  • the blocking agent d2 is applied from the outside of the retina R.
  • the blocking agent d2 may be applied from the inside of the retina R (the subretinal space A side).
  • the occluding agent d2 is ejected from the tip of the inner needle placed inside the retina R immediately before the inner needle is pulled out from the subretinal space A.
  • the viscosity of the occluding agent d2 By adjusting the viscosity of the occluding agent d2 to a predetermined value, it can be retained at the distal end of the inner needle.
  • the occlusive agent d2 By pulling out the inner needle from the retina R while the occlusive agent d2 is held at the distal end of the inner needle, the occlusive agent d2 can be attached to the inner side of the retina R. By adopting such a procedure, the perforation P can be closed from the inside of the retina R when the extraction from the retina R is completed.
  • the inner needle when the blocking agent d2 is discharged from the inner needle, the drug d1, the blocking agent d2, and the swelling agent can be selectively discharged through the lumen of the inner needle inserted into the outer needle.
  • the inner needle may be configured with a single lumen, or may be configured with a multi-lumen that can discharge each material individually.
  • a dedicated route for the drug d1, a dedicated route for the blocking agent d2, and a dedicated route for the swelling agent are exchanged.
  • each dedicated route may be replaced in the same manner as above, or the route of the blocking agent d2 may be replaced with the route of the drug d1 or the route of the swelling agent at the timing of ejecting the blocking agent d2. You can work.
  • the configurations described in each embodiment can be arbitrarily combined.
  • the inner and/or outer needles of the medical devices described in the third and fourth embodiments can be curved needles.
  • each part of the medical device can be arbitrarily changed as long as it is possible to puncture the retina, administer drugs into the subretinal space, and close the perforation formed in the retina. It is possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

[Problème] Fournir un instrument médical à l'aide duquel il est possible d'administrer un médicament dans la cavité sous-rétinienne et de boucher facilement et de manière fiable une perforation formée dans la rétine. [Solution] Selon la présente invention, un instrument médical (100) comporte une aiguille interne (120) servant à former une perforation (P) dans la rétine (R) d'un patient, et une aiguille externe (130) pourvue d'une lumière (121) apte à loger l'aiguille interne, l'aiguille interne étant pourvue d'une lumière (121) apte à distribuer un médicament (d1) administré dans la cavité sous-rétinienne (A) d'un patient et étant conçue de façon à pouvoir se déplacer le long de la lumière de l'aiguille externe, et l'aiguille externe étant conçue de façon à être apte à évacuer un agent d'obturation (d2) pour boucher la perforation.
PCT/JP2022/007488 2021-03-25 2022-02-24 Instrument médical WO2022202072A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-050969 2021-03-25
JP2021050969 2021-03-25

Publications (1)

Publication Number Publication Date
WO2022202072A1 true WO2022202072A1 (fr) 2022-09-29

Family

ID=83397022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/007488 WO2022202072A1 (fr) 2021-03-25 2022-02-24 Instrument médical

Country Status (1)

Country Link
WO (1) WO2022202072A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020133184A1 (en) * 2001-03-15 2002-09-19 Lorusso Frank J. Apparatuses and methods for transcleral cautery and subretinal drainage
JP2012515627A (ja) * 2009-01-23 2012-07-12 アイサイエンス・インターベンショナル・コーポレーション 網膜下アクセス装置
US20150112282A1 (en) * 2012-04-09 2015-04-23 Industry-Academic Cooperation Foundation, Yonsei University Hollow microneedle and subretinal syringe for subretinal injection or extraction

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020133184A1 (en) * 2001-03-15 2002-09-19 Lorusso Frank J. Apparatuses and methods for transcleral cautery and subretinal drainage
JP2012515627A (ja) * 2009-01-23 2012-07-12 アイサイエンス・インターベンショナル・コーポレーション 網膜下アクセス装置
US20150112282A1 (en) * 2012-04-09 2015-04-23 Industry-Academic Cooperation Foundation, Yonsei University Hollow microneedle and subretinal syringe for subretinal injection or extraction

Similar Documents

Publication Publication Date Title
JP4505219B2 (ja) 網膜下への薬剤送達のための方法およびデバイス
US8425473B2 (en) Subretinal access device
JP3688287B1 (ja) 眼科用インプラントを送達するための装置
JP4808356B2 (ja) 小型弁
AU2014367150B2 (en) Systems and methods for subretinal delivery of therapeutic agents
US20080281292A1 (en) Retractable Injection Port
WO2019090195A1 (fr) Système d'injection de fluide à gaz
WO2010024871A1 (fr) Cathéters à ballonnet ayant une pluralité d’aiguilles pour l’injection d’un ou de plusieurs agents thérapeutiques
AU2002316350A1 (en) Method and device for subretinal drug delivery
JP2008536625A (ja) デュアル・ニードル送りシステム
WO2009089409A2 (fr) Système d'injection intravitréen à canules coaxiales et son utilisation
JPH0630961A (ja) 眼科用カニューレ
CN113616417A (zh) 经弯针用于视网膜下施用治疗剂的装置
JP2012205697A (ja) カテーテル及びその製造方法
CN105902341B (zh) Tenon囊下注药装置
WO2022202072A1 (fr) Instrument médical
US11045353B2 (en) Ophthalmic surgical system with infusion fluid and substance delivery through an infusion cannula
CN114555016A (zh) 用于注射器的剂量夹组件
EP2968752B1 (fr) Aiguille d'injection de cellules
WO2021177217A1 (fr) Dispositif d'injection d'agent hémostatique
US20230301832A1 (en) Ophthalmic device
CN220989032U (zh) 一种视网膜精准注射装置
WO2020195352A1 (fr) Instrument de dosage et système de dosage d'une solution médicamenteuse
US20230111131A1 (en) Apparatus for subretinal injection
CN206315188U (zh) Tenon囊下注药装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22774870

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22774870

Country of ref document: EP

Kind code of ref document: A1